Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

Stock Information for Journey Medical Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Journey Medical Corporation

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Q32 Bio Sells Complement Inhibitor ADX-097
Akebia Announces Establishment of Rare Kidney Disease Pipeline
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
Akebia Therapeutics to Present at Upcoming Investor Conferences
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.